Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

KA Margolin, PY Liu, JM Unger, WS Fletcher… - Journal of cancer …, 1999 - Springer
The therapeutic benefit of adding interferon α (IFNα) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …
被引用次数：16 相关文章

Phase II trial of biochemotherapy with interferon, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

KA Margolin, PY Liu, JM Unger, WS Fletcher… - Journal of Cancer …, 1999 - infona.pl
The therapeutic benefit of adding interferon (IFN) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …

[引用][C] Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

KA Margolin, PY Liu, JM Unger… - Journal of …, 1999 - providence.elsevierpure.com
Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in
metastatic melanoma: a Southwest Oncology Group trial — Providence Skip to main …

Phase II trial of biochemotherapy with interferon [alpha], dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

KA Margolin, PY Liu, JM Unger… - Journal of Cancer …, 1999 - search.proquest.com
The therapeutic benefit of adding interferon α (IFNα) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …
[PDF] researchgate.net

[PDF][PDF] Phase II trial of biochemotherapy with interferon a, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

KA Margolin, PY Liu, JM Unger… - J Cancer Res Clin …, 1999 - researchgate.net
The therapeutic benefit of adding interferon o (IFNo) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …

[引用][C] Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a southwest oncology group trial

KA MARGOLIN, PY LIU, GR WEISS… - Journal of cancer …, 1999 - pascal-francis.inist.fr
Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in
metastatic melanoma : a southwest oncology group trial CNRS Inist Pascal-Francis CNRS …

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: A Southwest Oncology Group trial

KA Margolin, PY Liu, JM Unger… - Journal of Cancer …, 1999 - scholars.northwestern.edu
The therapeutic benefit of adding interferon α (IFNα) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

KA Margolin, PY LIU, JM Unger, WS Fletcher… - Journal of Cancer …, 1999 - elibrary.ru
The therapeutic benefit of adding interferon α (IFNα) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …

Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.

KA Margolin, PY Liu, JM Unger… - Journal of Cancer …, 1999 - europepmc.org
The therapeutic benefit of adding interferon alpha (IFNalpha) to established single-agent
and combination chemotherapy regimens for the treatment of metastatic melanoma has not …

[引用][C] Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a southwest oncology group trial

KA MARGOLIN, PY LIU, JM UNGER… - Journal of cancer …, 1999 - Springer